Thoughts on Cellectis’s CAR-T Program; Potential UCARTCS1 Protocol Changes; Q2 2020 Earnings Call
On Wednesday, August 5, Cellectis held their Q2 2020 conference call (press release). As expected, the company discussed the recent FDA hold on the UCARTCS1 Ph1 MELANI-01 trial in r/r MM. Management also stated that interim data will be presented for either UCART22 or UCART123 in Q4 2020, and that the Paris and Raleigh manufacturing sites remain on track to open later in 2020 and in 2021, respectively. Below, Celltelligence provides key takeaways from the call, and thoughts on Cellectis’s CAR-T program, particularly around the anticipated next steps for UCARTCS1.
About The Author
Matthew has been a thought leader in the high-growth therapeutic areas of diabetes and cardiovascular medicine since 2006, making regular attendance at large and small CV/met scientific meetings and an architect of novel methods for assessing market opportunities. He has over a decade of experience in leading CV/met consulting engagements, is a published author in PM360 and Diabetes Technology & Therapeutics, and has been quoted in The Pink Sheet on anti-thrombotics.
If you receive our email blasts, you already have an account. Log in now
You can read the article’s full content online after purchase.